New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
10:47 EDTHARTHarvard Apparatus says response from FDA meeting 'very favorable'
Harvard Apparatus said in investor presentation slides that its pre-Investigational New Drug meeting with the FDA at the end of January yielded a "very favorable response." The company expects an orphan designation determination by the FDA in Q2. Harvard added that it has approximately two years of capital at current burn rates and no debt. Harvard said that eight patients are using its bioreactor technology with six of those alive at February 2014. The two that did not survive died of unrelated causes, it said. Shares of Harvard Apparatus are up 6%, or 42c, to $7.71 in morning trading.
News For HART From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
08:31 EDTHARTHarvard Apparatus says patient in transplant study passes away
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use